Sylvia Gruenewald
Bayer (Germany)(DE)
Publications by Year
Research Areas
Cancer, Hypoxia, and Metabolism, Fibroblast Growth Factor Research, Bladder and Urothelial Cancer Treatments, Epigenetics and DNA Methylation, RNA modifications and cancer
Most-Cited Works
- → Capturing tumor complexity in vitro: Comparative analysis of 2D and 3D tumor models for drug discovery(2016)241 cited
- → Metabolic pathway analyses identify proline biosynthesis pathway as a promoter of liver tumorigenesis(2019)137 cited
- → Abstract 1739: Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial(2014)10 cited
- → Abstract 3080: Activity of pan-FGFR inhibitor rogaratinib and PI3K inhibitor copanlisib in preclinical urothelial bladder cancer models(2019)2 cited
- → Abstract 1026: Novel Tie2 inhibitor with in vivo efficacy in disseminated hematological tumor models in mice(2014)1 cited
- → Abstract 4793: Preclinical evaluation of the combination rogaratinib and copanlisib in HNSCC and HCC in preclinical in vitro and in vivo models(2019)1 cited
- → Abstract 3477: Metabolic pathway analyses identify proline biosynthesis as a promoter of liver carcinogenesis(2018)1 cited
- → Abstract 1164: Metabolic responses in cancer cells with differential susceptibility to GLUT1 inhibition(2015)1 cited
- → Abstract 1163: Phosphoserine aminotransferase 1 (PSAT1) as a novel anti-tumor target in hepatocellular carcinoma(2015)1 cited